LSE · ABDX.L
Abingdon Health Plc
£0.09£0.00 (0.0%)
Abingdon Health Plc’s quoted price sits in the lower half of its reported 52-week range, 30.77% below the high.
Loading market information…
LSE · GENI.L · GBp
Stock price, earnings
Quote as of Oct 29, 2026, 04:35 PM UTC. Cached market data; not a live quote.
One-year closing-price history · GBp. Historical prices are not a forecast.
GENinCode plc’s quoted price sits in the lower half of its reported 52-week range, 86.53% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
GENinCode plc’s next earnings report is currently expected on Jun 8, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow GENinCode plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
GENinCode Plc specializes in the creation and commercialization of advanced genetic tests designed to forecast potential health risks based on an individual's DNA. Operating in both the United Kingdom and internationally, their predictive technology empowers individuals and medical professionals alike with proactive health management and targeted intervention strategies. The company's sophisticated molecular diagnostics leverage a combination of clinical algorithms and artificial intelligence to deliver precise patient risk assessments, thereby anticipating the onset of various diseases. Among their specialized tests are: Cardio inCode: A patented genetic assay designed to guide individuals in cardiovascular prevention. Lipid inCode: A genetic diagnostic tool that analyzes seven specific genes associated with familial hypercholesterolemia. SUDD inCode: A genetic test to identify the underlying causes of sudden cardiac death and inherited heart conditions. Thrombo inCode: This test assesses 12 genetic variants linked to hereditary thrombophilia and the general risk of thrombosis (blood clots). Thrombo inCode Reproductive Health: Offering crucial insights into thrombophilia risks particularly relevant to prospective pregnancies. Established in 2018, GENinCode Plc maintains its headquarters in Oxford, United Kingdom.
Latest available per-share figures in GBP. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:36 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2023 | Jun 8, 2023 | -£0.03-4.01% vs estimate | £766.00K-0.26% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
£0.09£0.00 (0.0%)
Abingdon Health Plc’s quoted price sits in the lower half of its reported 52-week range, 30.77% below the high.
£0.27£0.00 (0.0%)
RUA Life Sciences plc’s quoted price sits in the upper half of its reported 52-week range, 12.9% below the high.
£0.01-£0.00 (-2.5%)
Genedrive Plc’s quoted price sits in the lower half of its reported 52-week range, 37.1% below the high.
£0.02-£0.00 (-3.95%)
Genflow Biosciences Plc’s quoted price sits in the lower half of its reported 52-week range, 41.51% below the high.
£0.01£0.00 (0.0%)
CelLBxHealth plc’s quoted price sits in the lower half of its reported 52-week range, 77.68% below the high.
£0.06+£0.00 (+2.65%)
OptiBiotix Health Plc’s quoted price sits in the lower half of its reported 52-week range, 35.56% below the high.
£0.01+£0.00 (+4.29%)
Proteome Sciences plc’s quoted price sits in the lower half of its reported 52-week range, 66.82% below the high.
£0.01£0.00 (0.0%)
Cizzle Biotechnology Holdings Plc’s quoted price sits in the lower half of its reported 52-week range, 70.51% below the high.
